pharmaphorum| News & views on pharma and biotech’s evolving future

Patients

Stem the bleeding: Rising to meet the growing demand for CGT...

Following World Blood Donor Day, a look at the continued need for more donors of blood, but also cord blood and perinatal tissue, too.

News

Eisai claims UK grant to expand manufacturing site

Eisai has been given a grant from the UK that will support a £48m plan to add cold chain capabilities to its facility in Hatfield, Hertfordshire.

Market Access

Can direct-to-employer models close the GLP-1 obesity care g...

News

Key pipeline drug for Lundbeck delivers in Cushing syndrome

Lundbeck has reported positive trial results with Cushing's therapy asedebart, a key R&D prospect as it faces a patent cliff in the next few years.

News

Two boxes and vials of Talvey, different doses

Data could move J&J's Talvey earlier in myeloma therapy

Johnson & Johnson's Talvey looks set to move second-line in multiple myeloma treatment, based on the results of the MonumenTAL-3 trial at EHA 2026.

Featured Content

Patients

Stem the bleeding: Rising to meet the growing demand for CGT...

Following World Blood Donor Day, a look at the continued need for more donors of blood, but also cord blood and perinatal tissue, too.

Spotlight on

ASCO 2026

As the buzz increases in volume and the clock to kick-off counts down, keep an eye on this Spotlight On page for content coming to you from onsite in Chicago. We’ll have features and video content rolling out as the presentations unfold day by day.

/themes/custom/pharmaphorum_theme/library/img/article-label-image/register.png

Digital

Sponsored

Discover a new era of healthcare panel engagement: Grounded ...

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.

Patients

pharmaphorum podcast Episode 263, Rebecca Guntern - Sandoz

Biosimilars & patient access independent of geographies or s...

Rebecca Guntern, Sandoz' CCO, discusses the ‘golden decade’ for generics and biosimilars as so many blockbuster drugs come off patent.

Patients

ASCO 2026: Quality of life, not just quantity, with Dr Harol...

Dr Harold Keer, chief medical officer at Taiho Oncology, goes in-depth about why his company places such an emphasis on oral formulations.

R&D

Sponsored

From Alzheimer’s disease research to the real-world setting:...

In a new white paper, Lucid Strategy Consulting suggests three key themes for pharma strategists seeking market leadership in the Alzheimer's space.

Newsletters and Deep Dive
digital magazine

Latest News

News

Eisai claims UK grant to expand manufacturing site

Eisai has been given a grant from the UK that will support a £48m plan to add cold chain capabilities to its facility in Hatfield, Hertfordshire.

News

Key pipeline drug for Lundbeck delivers in Cushing syndrome

Lundbeck has reported positive trial results with Cushing's therapy asedebart, a key R&D prospect as it faces a patent cliff in the next few years.

News

Data could move J&J's Talvey earlier in myeloma therapy

Johnson & Johnson's Talvey looks set to move second-line in multiple myeloma treatment, based on the results of the MonumenTAL-3 trial at EHA 2026.

News

NHS study launched to tackle antimicrobial resistance threat

A new study will attempt to improve screening for CPE, one of the fastest-growing drug-resistant bacterial threats facing hospitals in England.

Views & Analysis

Patients

Stem the bleeding: Rising to meet the growing demand for CGT...

Following World Blood Donor Day, a look at the continued need for more donors of blood, but also cord blood and perinatal tissue, too.

Sales & Marketing

Scissors snipping off half of workforce concept

The hidden risks of biotech layoffs: Why cost-cutting trigge...

Reducing your team without a strategic risk plan actually spikes corporate vulnerability more than it lowers burn rates.

Patients

Hands holding graphic representation of a kidney on a blue background

The forgotten few: Why the kidney transplant system is faili...

While innovation has reshaped therapeutic areas like oncology, transplant medicine has, by comparison, stood still.

Sales & Marketing

Agile learning focused on driving change: Lessons for Centre...

Less than 30% of digital transformations succeed across industries, while biopharma remains significantly behind (~20% succeed), with only a small minority of companies achieving scaled, en

Deep Dive

Market Access

Market Access 2026

Market Access

Five dynasties that built modern pharma

Market Access

MFN and TrumpRx: What’s the real impact for the American con...

Market Access

The expanding role of early-phase trials in modern drug deve...

White Papers & Webinar

R&D

Sponsored

From Alzheimer’s disease research to the real-world setting:...

In a new white paper, Lucid Strategy Consulting suggests three key themes for pharma strategists seeking market leadership in the Alzheimer's space.

Digital

Sponsored

Discover a new era of healthcare panel engagement: Grounded ...

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png

R&D

From obesity to outcomes abstract visual

Sponsored

The future of cardiometabolic trials: From obesity to outcom...

Gain practical insight into how leading experts are designing the next generation of cardiometabolic trials in an upcoming webinar from hVIVO

R&D

Sponsored

A data-driven guide to small molecule drug discovery and dev...

A new white paper from Excelra takes a closer look at how discovery teams actually experience the small molecule development journey.

Podcasts & Video

Patients

ASCO 2026: Quality of life, not just quantity, with Dr Harol...

Dr Harold Keer, chief medical officer at Taiho Oncology, goes in-depth about why his company places such an emphasis on oral formulations.

Oncology

ASCO 2026: Takeda’s Innovent deal bears fruit, with Teresa B...

Teresa Bitetti and PK Morrow share some of the highlights from Takeda’s data at the show as well as discussing how it fits into their larger strategy.

Patients